MIRUM PHARMACEUTICALS, INC. (MIRM)
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
📈 **POSITIVE** • High confidence analysis (91%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business